Oblita Therapeutics SRL
Oblita Therapeutics reported total assets of 418,521 € at the end of the 2025 financial year (annual accounts filed with the NBB on 28 Aug 2026).
The score of Oblita Therapeutics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -75 % Total assets +18 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Oblita Therapeutics's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −13,569 € | ||||
| Equity | 33,262 € | ||||
| Cash | 2,954 € | ||||
| EBITDA | 112,288 € | ||||
| Total assets | 418,521 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 28 Aug 2026
- Year ended 31 Dec 2024filed on 29 Aug 2025
- Year ended 31 Dec 2023filed on 30 Aug 2024
- Year ended 31 Dec 2022filed on 31 Aug 2023
- Year ended 31 Dec 2021filed on 31 Aug 2022
Oblita Therapeutics's financial analysis
- Solvency7.9%sector median: 61.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Oblita Therapeutics
Oblita Therapeutics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0832.102.424
- VAT number
- BE0832102424
- Peppol
- Registered · 0208:0832102424 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 20 Dec 2010
- Registered office
- 2980 Zoersel
- Latest accounts
- 2025 · filed on 28 Aug 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Oblita Therapeutics (SRL) has been based in Zoersel since 2010, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of 13,569 € and equity of 33,262 €; its revenue is not published. Its solvency stands at 7.9%, below the median of its sector (61.7%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Oblita Therapeutics
Companies in the same business, of comparable size and area, outside its group.
- Retail Management Claudia Boeren Activities of holding companies Zoersel · balance sheet 410,418 €
- Multimanagement Business and other management consultancy activities Fernelmont · balance sheet 546,508 €
- Quester Activities of holding companies Wielsbeke · balance sheet 277,874 €
- Funnel Food Marketing Activities of holding companies Antwerp · balance sheet 445,365 €
- Paper Street Activities of holding companies Brussels · balance sheet 338,768 €
- Artemis Activities of holding companies De Panne · balance sheet 667,780 €
- Primetime Consult Activities of holding companies Tielt-Winge · balance sheet 718,657 €
- CH2B Activities of holding companies Schilde · balance sheet 678,780 €
Frequently asked questions about Oblita Therapeutics
What is the revenue of Oblita Therapeutics?
Oblita Therapeutics files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Oblita Therapeutics?
In Belgium, the VAT number is the company number prefixed with BE: BE0832102424 for Oblita Therapeutics, if the company is VAT-registered. Its company number (CBE) is 0832.102.424.
Where is the registered office of Oblita Therapeutics?
According to the CBE register, the registered office of Oblita Therapeutics is in 2980 Zoersel.
What is the equity of Oblita Therapeutics?
At the close of the 2025 financial year, the equity of Oblita Therapeutics amounts to 33,262 €, a solvency of 7.9% of total assets.
Who manages Oblita Therapeutics?
The register lists 1 active mandates at Oblita Therapeutics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Oblita Therapeutics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →